ASTROTECH Corp. Files 2024 10-K: $2.5M Assets, $1.7M Liabilities

Ticker: ASTC · Form: 10-K · Filed: Sep 20, 2024 · CIK: 1001907

Sentiment: neutral

Topics: 10-K, financials, assets, liabilities

TL;DR

ASTROTECH Corp. 2024 10-K: $2.5M assets, $1.7M liabilities. FY ends 06/30.

AI Summary

ASTROTECH Corp. filed its 10-K for the fiscal year ending June 30, 2024, reporting total assets of $2.5 million and total liabilities of $1.7 million. The company's net revenue for the period was not explicitly stated but its operating expenses were $280,898. ASTROTECH Corp. is incorporated in Delaware and its principal business address is in Austin, Texas.

Why It Matters

This filing provides a snapshot of ASTROTECH Corp.'s financial health as of June 30, 2024, detailing its assets and liabilities, which are crucial for investors and creditors to assess the company's stability and performance.

Risk Assessment

Risk Level: medium — The company has significantly more liabilities than assets, indicating potential financial strain.

Key Numbers

Key Players & Entities

FAQ

What was ASTROTECH Corp.'s net revenue for the fiscal year ending June 30, 2024?

The provided filing excerpt does not explicitly state ASTROTECH Corp.'s net revenue for the fiscal year ending June 30, 2024.

What is the company's primary industry classification?

ASTROTECH Corp. is classified under 'LABORATORY ANALYTICAL INSTRUMENTS' with SIC code 3826.

What is the company's state of incorporation?

ASTROTECH Corp. is incorporated in Delaware (DE).

What were the company's total current liabilities as of June 30, 2024?

The filing indicates total current liabilities were $1,681,729 as of June 30, 2024.

What is the company's filing history regarding name changes?

ASTROTECH Corp. was formerly known as SPACEHAB INC until October 6, 1995, and its name was changed on March 10, 2009.

Filing Stats: 4,434 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2024-09-20 08:45:50

Key Financial Figures

Filing Documents

Business

Item 1. Business 7

Risk Factors

Item 1A. Risk Factors 25

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 44

Cybersecurity

Item 1C. Cybersecurity 44

Properties

Item 2. Properties 45

Legal Proceedings

Item 3. Legal Proceedings 45

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 46 PART II 46

Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 46

Reserved

Item 6. Reserved 46

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 46

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 54

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 55

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 81

Controls and Procedures

Item 9A. Controls and Procedures 81

Other Information

Item 9B. Other Information 82 PART III 82

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 82

Executive Compensation

Item 11. Executive Compensation 82

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 82

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 82

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 82 PART IV 83

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 83

Form 10-K Summary

Item 16. Form 10-K Summary 86

SIGNATURES

SIGNATURES 87 4 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Form 10-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "plans," "believes," "estimates," "expects," "intends" and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to: The adverse impact of recent inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing war in Ukraine and the COVID-19 pandemic; Our ability to successfully pursue our business plan and execute our strategy, including our collaboration with Cleveland Clinic; The effect of economic and political conditions in the United States or other nations that could impact our ability to sell our products and services or gain customers; Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers; The impact of trade barriers imposed by the U.S. government, such as import/export duties and restrictions, tariffs and quotas, and potential corresponding actions by other countries in which we conduct our business; Technological difficulties and potential legal claims arising from any technological difficulties; The risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation; Uncertainty in government funding and support for key programs, grant opportunities, or procurem

Business

Item 1. Business Our Company The terms "Astrotech", "the Company", "we", "us", or "our" refer to Astrotech Corporation (Nasdaq: ASTC), a Delaware corporation organized in 1984. Our use of "products" and "devices" refer to the TRACER 1000, BreathTest-1000, AGLAB 1000, and Pro-Control 1000 along with related accessories and consumables. We are commercializing the Astrotech Mass Spectrometer Technology platform ("AMS Technology") through application specific, wholly owned subsidiaries. Our mission is to expand access to mass spectrometry ("MS") and its use through the deployment of devices designed specifically for the appropriate levels of precision required in high-volume, real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. We achieve our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS field work, and enabling multiple configurations for sample intake options. Since the Tracer 1000 was certified by the European Civil Aviation Conference ("ECAC") in 2019, our customers have deployed our devices in approximately 30 locations across 14 countries throughout Europe and Asia. Our Business Units Our efforts are focused on commercializing our platform mass spectrometry technology through our wholly-owned subsidiaries: Astrotech Technologies, Inc. ("ATI") owns and licenses the intellectual property related to the AMS Technology. 1 st Detect Corporation ("1 st Detect") is a manufacturer of explosives trace detectors ("ETDs") and narcotics trace detectors ("NTDs") developed for use in security and detection at airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, and law enforcement centers. 1 st Detect holds an exclusive AMS Technology license from ATI for air passenger an

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing